BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  Positive Data in Psoriatic Arthritis, Lupus Presented at EULAR

  Acelyrin, Affibody AB and Inmagene Biopharmaceuticals presented positive Phase II data for izokibep in psoriatic arthritis, while Aurinia’s Lupkynis hit post-hoc treatment targets in lupus nephritis.

  June 3, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  FDA Extends Review for Amylyx ALS Drug to September

  Amylyx Pharmaceuticals shared news that the FDA has extended the review period for AMX0035, a combination drug treatment with the potential to treat patients with ALS.

  June 3, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano M.S.
• 

  Lone Star Bio

  Aeglea Stumbles in First BLA Attempt as FDA Issues RTF

  The FDA requested more data on effectiveness, particularly evidence that shows plasma arginine and metabolic reduction can predict clinical benefit in patients living with ARG1-D.

  June 3, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Scientists Reset the Clock on Aging through Gene Manipulation

  While tools to reverse age-related cellular dysfunction haven’t yet reached the masses, two research studies have emerged this week that hint at progress.

  June 3, 2022

   · 

  3 min read

   · 

  Jazmine Colatriano M.S.
• 

  Business

  Merck KGaA Strikes $550M Deal with Proxygen in Latest Protein Degradation Deal

  Proxygen partnered with Germany-based Merck to jointly identify and develop molecular glue degraders for clinical research.

  June 3, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Sanofi and Immunocore Pair High Potential Molecules for Metastatic Skin Cancers

  Sanofi will study its SAR444245 in combination with Immunocore’s KIMMTRAK in HLA-A*02:01 positive patients with advanced unresectable or metastatic skin cancers.

  June 3, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Athersys Culls 70% of Staff in Effort to Prioritize MultiStem Programs

  Shares of Cleveland-based Athersys, Inc. are plunging Friday after the company announced a strategic restructuring that will result in the slashing of 70% of its workforce.

  June 3, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  BMS Picks up High Potential NSCLC Drug in $4.1B Turning Point Acquisition

  Bristol Myers Squibb announced Friday that it is acquiring San Diego-based Turning Point Therapeutics in a deal totaling about $4.1 billion.

  June 3, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Sapience, Intensity, Kazia and Transcenta Tout Early Success at ASCO

  Four life sciences companies posted previews of their respective programs ahead of the American Society of Clinical Oncology (ASCO) annual meeting on June 5, 2022.

  June 3, 2022

   · 

  3 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Clinical Catch-Up: NIH’s COVID-19 Trial and All About ASCO

  It was a busy, busy week for clinical trial news and updates, largely driven by the annual ASCO meeting taking place June 3-7 in Chicago.

  June 3, 2022

   · 

  13 min read

   · 

  Mark Terry